And so…we come to the most painful, controversial, and confusing of the definitions… ”intervention” and “interventional”.
Ideally, we would classify studies according to the level of intervention i.e., interventional, low intervention, and non-interventional. However, most regulators have been hesitant to define ‘intervention’ in their regulations. Only a few countries (e.g., USA, France, and South Africa) [refs 1 to 3] have defined “intervention” in the context of clinical trials.
If ‘intervention’ isn’t defined in the regulations of the region of interest it becomes difficult (impossible) to define what is, and is not, an intervention, and therefore what is, and is not, a clinical trial.
There is a simple solution. Most countries define a ‘clinical trial’.
For example, in Europe: ‘Clinical trial’ means a clinical study which fulfils any of the following conditions [ref 4]:
(a) the assignment of the subject to a particular therapeutic strategy is decided in advance and does not fall within normal clinical practice of the Member State concerned;
(b) the decision to prescribe the investigational medicinal products is taken together with the decision to include the subject in the clinical study; or
(c) diagnostic or monitoring procedures in addition to normal clinical practice are applied to the subjects
So…when classifying a clinical study, the recommendation is to determine whether the proposed study is a clinical trial.
If the study isn’t a clinical trial, then what is it?
In Europe, a ‘non-interventional study’ is a clinical study other than a clinical trial [ref 4].
Therefore, in Europe both clinical trials and non-interventional studies (NIS) are investigations in humans that involves a medicinal product. Whereas, clinical trials involve protocol-defined healthcare interventions, and NIS do not.
References:
[1] Section III.A of the FDA Guidance – Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products (August 2023): https://www.fda.gov/media/171667/download
[2] Article L1121-1 of the Public Health Code (CSP): https://www.legifrance.gouv.fr/codes/article_lc/LEGIARTI000032722870/
[3] Glossary of the Department of Health – Ethics in Health Research Guidelines: Principles, Processes and Structures (2015): https://www.health.gov.za/wp-content/uploads/2022/05/NHREC-DoH-2015-Ethics-in-Health-Research-Guidelines-1.pdf
[4] Article 2 of the EU Clinical Trials Regulation (Regulation EU/536/2014): https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02014R0536-20221205
In essence, definitions lay the groundwork for accurate, consistent, and meaningful research, especially in areas where the data and its sources are as diverse and complex as in RWD and RWE.
Share this story...
Germany – AKEK – Secondary Use of Patient Data for Research Purposes
RWE 201 - Germany – AKEK – Secondary Use of Patient Data for Research Purposes AKEK Statement (Aug 2023): https://www.akek.de/wp-content/uploads/Stellungnahme-EHDS_V7.1.pdfThe Working Group of Medical Ethics Commissions in Germany (AKEK) [...]
UK – NHS England – Federated Data Platform – Lessons Learned from the General Practice Data for Planning and Research Initiative
RWE 201 - UK – NHS England – Federated Data Platform – Lessons Learned from the General Practice Data for Planning and Research Initiative NHS England – Federated Data [...]
UK – NICE – RWE Framework
RWE 201 - UK – NICE – RWE Framework NICE RWE Framework: https://www.nice.org.uk/corporate/ecd9/chapter/overviewReal-world data (RWD) encompasses various types of information on patient health, care delivery, and experiences collected outside [...]
UK – MHRA – Randomised Controlled Trials Using Real World Data
RWE 201 - UK – MHRA – Randomised Controlled Trials Using Real World Data MHRA RWD Guidance: https://www.gov.uk/government/publications/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions/mhra-guideline-on-randomised-controlled-trials-using-real-world-data-to-support-regulatory-decisions The MHRA guideline focuses on sponsors planning to [...]
UK – MHRA – Use of RWD to Support Regulatory Decisions
RWE 201 - UK – MHRA – Use of RWD to Support Regulatory Decisions MHRA RWD Guidance: https://www.gov.uk/government/publications/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions The MHRA (Medicines and Healthcare products Regulatory Agency) [...]
Real World Evidence (RWE) 201 – France – Haute Autorité de Santé (HAS) – Real World Study Guide
RWE 201 - France – Haute Autorité de Santé (HAS) – Real World Study Guide HAS Real World Stidy Guide: https://www.has-sante.fr/upload/docs/application/pdf/2021-06/real-world_studies_for_the_assessment_of_medicinal_products_and_medical_devices.pdfThe Haute Autorité de Santé (HAS), France's National Authority [...]







